Limits...
Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy.

Wang XB, Jiang XR, Yu XY, Wang L, He S, Feng FY, Guo LP, Jiang W, Lu SH - Cancer Sci. (2014)

Bottom Line: The results showed that the serum MIC1 of ESCC was significantly higher than normal groups (P < 0.001), and was positively associated with tumor invasion (P = 0.030) as well as lymph node metastasis (P = 0.007).The antibody of MIC1 inhibited the tumor growth (P < 0.001), and showing preference for tumor tissues in xenograft model.The decreased formation of neovascularization lumen may be involved in the mechanism.

View Article: PubMed Central - PubMed

Affiliation: State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Show MeSH

Related in: MedlinePlus

Inhibition of anti-macrophage inhibitory factor 1 (MIC1) antibody for human esophageal squamous cell carcinoma (ESCC) xenografts in vivo and its localization. (a) The volume of tumors in experimental and control groups by continuous observation. Data are presented as the mean ± standard error (SE), n = 10. (b) The weight of tumors in experimental and control groups. Data are presented as the mean ± SE, n = 10. (c) Dylight755 fluorescence dye and Dylight755 coupled anti-hMIC1 antibody 7c7 in S4 xenograft tumor 3 h and 3 days after IP and IT injection measured in vivo. IP, intraperitoneal injection; IT, intratumor injection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317821&req=5

fig04: Inhibition of anti-macrophage inhibitory factor 1 (MIC1) antibody for human esophageal squamous cell carcinoma (ESCC) xenografts in vivo and its localization. (a) The volume of tumors in experimental and control groups by continuous observation. Data are presented as the mean ± standard error (SE), n = 10. (b) The weight of tumors in experimental and control groups. Data are presented as the mean ± SE, n = 10. (c) Dylight755 fluorescence dye and Dylight755 coupled anti-hMIC1 antibody 7c7 in S4 xenograft tumor 3 h and 3 days after IP and IT injection measured in vivo. IP, intraperitoneal injection; IT, intratumor injection.

Mentions: The data on tumor weight, volume and inhibitory effect of all groups was evaluated. We found that both 2 and 10 mg/kg dosing group yielded significantly tumor inhibition (32% and 46% respectively, P < 0.001), and the inhibitory effect has a dose-dependent relationship (Fig. 4a,b, Fig. S2a). None of the mice died during the assay, and mice treated with the antibody had a more weight gain (Fig. S2b).


Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy.

Wang XB, Jiang XR, Yu XY, Wang L, He S, Feng FY, Guo LP, Jiang W, Lu SH - Cancer Sci. (2014)

Inhibition of anti-macrophage inhibitory factor 1 (MIC1) antibody for human esophageal squamous cell carcinoma (ESCC) xenografts in vivo and its localization. (a) The volume of tumors in experimental and control groups by continuous observation. Data are presented as the mean ± standard error (SE), n = 10. (b) The weight of tumors in experimental and control groups. Data are presented as the mean ± SE, n = 10. (c) Dylight755 fluorescence dye and Dylight755 coupled anti-hMIC1 antibody 7c7 in S4 xenograft tumor 3 h and 3 days after IP and IT injection measured in vivo. IP, intraperitoneal injection; IT, intratumor injection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317821&req=5

fig04: Inhibition of anti-macrophage inhibitory factor 1 (MIC1) antibody for human esophageal squamous cell carcinoma (ESCC) xenografts in vivo and its localization. (a) The volume of tumors in experimental and control groups by continuous observation. Data are presented as the mean ± standard error (SE), n = 10. (b) The weight of tumors in experimental and control groups. Data are presented as the mean ± SE, n = 10. (c) Dylight755 fluorescence dye and Dylight755 coupled anti-hMIC1 antibody 7c7 in S4 xenograft tumor 3 h and 3 days after IP and IT injection measured in vivo. IP, intraperitoneal injection; IT, intratumor injection.
Mentions: The data on tumor weight, volume and inhibitory effect of all groups was evaluated. We found that both 2 and 10 mg/kg dosing group yielded significantly tumor inhibition (32% and 46% respectively, P < 0.001), and the inhibitory effect has a dose-dependent relationship (Fig. 4a,b, Fig. S2a). None of the mice died during the assay, and mice treated with the antibody had a more weight gain (Fig. S2b).

Bottom Line: The results showed that the serum MIC1 of ESCC was significantly higher than normal groups (P < 0.001), and was positively associated with tumor invasion (P = 0.030) as well as lymph node metastasis (P = 0.007).The antibody of MIC1 inhibited the tumor growth (P < 0.001), and showing preference for tumor tissues in xenograft model.The decreased formation of neovascularization lumen may be involved in the mechanism.

View Article: PubMed Central - PubMed

Affiliation: State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Show MeSH
Related in: MedlinePlus